Anti-retroviral treatment using growth hormone

Abstract

The subject invention pertains to methods of treating HIV-1 infected subject comprising the administration of growth hormone to a subject infected by HIV-1. The subject may be undergoing co-administration of anti-retroviral therapies (ARTs), may be untreated with anti-retroviral drugs (ARDs) or may be in a period of time where no ART is being administered. Growth hormone may be administered at a fixed dosage for a set period of time or may be administered at a first dosage for a first period of time that may then be increased or decreased to a second dosage for a second period of time.

We claim: 
     
         1 . A method of treating an HIV-1 infected subject comprising the administration of growth hormone (GH) to a subject infected with HIV-1. 
     
     
         2 . The method according to  claim 1 , said method further comprising the measuring the size of the replication competent HIV reservoir in said subject. 
     
     
         3 . The method according to  claim 2 , said method comprising measuring the size of the replication competent HIV reservoir in said subject prior to the administration of GH to said subject and after the administration of GH to the subject. 
     
     
         4 . The method according to  claim 1 , wherein GH is co-administered to a subject with one or more anti-retroviral drug (ARD). 
     
     
         5 . The method according to  claim 4 , wherein said one or more anti-retroviral drug is selected from Abacavir; Didanosine; Emtricitabine; Lamivudine; Stavudine; Tenofovir disoproxil fumarate; Tenofovir alafenamide; Zalcitabine; Zidovudine; Delavirdine; Efavirenz; Etravirine; Nevirapine; Rilpivirine; Amprenavir; Atazanavir; Darunavir; Fosamprenavir; Indinavir; Lopinavir/Ritonavir; Nelfinavir; Ritonavir; Saquinavir; Tipranavir; Enfuvirtide; Maraviroc; Dolutegravir; Elvitegravir; Raltegravir; and combinations thereof. 
     
     
         6 . A method of treating an HIV-1 infected subject comprising the administration of a first dose of growth hormone (GH) to a subject infected with HIV-1 for a first period of time followed by the administration of a second dose of growth hormone (GH) to said subject for a second period of time. 
     
     
         7 . The method according to  claim 6 , said method further comprising the measuring the size of the replication competent HIV reservoir in said subject. 
     
     
         8 . The method according to  claim 7 , said method comprising measuring the size of the replication competent HIV reservoir in said subject prior to the administration of said first dose of GH to said subject. 
     
     
         9 . The method according to  claim 7 , said method comprising measuring the size of the replication competent HIV reservoir in said subject after the administration of said first dose of GH to said subject. 
     
     
         10 . The method according to  claim 7 , said method comprising measuring the size of the replication competent HIV reservoir in said subject prior to the administration of said first dose of GH to said subject and at the conclusion of said first time period. 
     
     
         11 . The method according to  claim 7 , said method comprising measuring the size of the replication competent HIV reservoir in said subject prior to the administration of said first dose of GH to said subject, at the conclusion of said first period of time and at the conclusion of said second time period where said second dose of GH is administered. 
     
     
         12 . The method according to  claim 7 , wherein the size of the replication competent HIV reservoir in said subject is measured prior to the administration of said first dose of GH to said subject and at multiple time points after the administration of said first dose of GH to the subject and multiple times after the administration of said second dose of GH to the subject. 
     
     
         13 . The method according to  claim 6 , wherein said first and said second doses of GH are co-administered to a subject with one or more anti-retroviral drug (ARD). 
     
     
         14 . The method according to  claim 13 , wherein said one or more anti-retroviral drug is selected from Abacavir; Didanosine; Emtricitabine; Lamivudine; Stavudine; Tenofovir disoproxil fumarate; Tenofovir alafenamide; Zalcitabine; Zidovudine; Delavirdine; Efavirenz; Etravirine; Nevirapine; Rilpivirine; Amprenavir; Atazanavir; Darunavir; Fosamprenavir; Indinavir; Lopinavir/Ritonavir; Nelfinavir; Ritonavir; Saquinavir; Tipranavir; Enfuvirtide; Maraviroc; Dolutegravir; Elvitegravir; Raltegravir; and combinations thereof. 
     
     
         15 . The method according to  claim 6 , wherein said subject has not been treated with an ARD. 
     
     
         16 . The method according to  claim 6 , wherein said subject is in an anti-retroviral therapy (ART) free period. 
     
     
         17 . The method according to  claim 13 , wherein said subject has undergone ART for period of: at least 6 months; at least 12 months; at least 18 months; or at least 24 months prior to treatment with GH. 
     
     
         18 . The method according to  claim 6 , wherein said second dose is a reduced dose of GH. 
     
     
         19 . The method according to  claim 18 , wherein said first dose of GH is administered in an amount of about 2 mg/day to about 5 mg/day and said second dose is administered in an amount of about 1 mg/day to about 4 mg/day. 
     
     
         20 . The method according to  claim 19 , wherein said first dose of GH is administered in an amount of about 3 mg/day and said second dose of GH is administered in an amount of about 1.5 mg/day. 
     
     
         21 . The method according to  claim 6 , wherein said subject is treated for a first period that ranges between about 2 weeks and about 52 weeks and a second period that ranges between about 2 and about 52 weeks. 
     
     
         22 . The method according to  claim 21 , wherein said first period is a period of about 24 weeks and said second period is a period of about 24 weeks. 
     
     
         23 . The method according to  claim 6 , wherein said second dose is an increased dose of GH. 
     
     
         24 . The method according to  claim 23 , wherein said first dose of GH is administered in an amount of about 2 mg/day to about 5 mg/day and said second dose is administered in an amount of about 3.5 mg/day to about 25 mg/day.